Jenny Kim's questions to INmune Bio Inc (INMB) leadership • Q2 2025
Question
Jenny Kim of BTIG asked about potential refinements to the EMAC endpoint measurement and the registrational precedent for the NPI behavioral marker in FDA discussions.
Answer
VP of Neuroscience, CJ Barnum, explained that the EMAC performed as expected, capturing cognitive change in the high-inflammation patient subgroup. He expressed confidence that the FDA would have a favorable opinion of EMAC, noting its use by several other companies and upcoming publications, which helps build scientific consensus. The question regarding the NPI was not fully addressed due to audio issues.